Folate-conjugated herpes simplex virus for retargeting to tumor cells
Folate-conjugated herpes simplex virus for retargeting to tumor cells
复制标题
叶酸结合的单纯疱疹病毒重新靶向肿瘤细胞
DOI：
10.1002/jgm.3177
复制
发表时间：
2020
影响因子：
3.5
通讯作者：
Gu Dian-Na
中科院分区：
文献类型：
--
作者：
Ye Zhi-Qiang;Zou Chang-Lin;Chen Han-Bin;Lv Qi-Yuan;Wu Ruo-Qi;Gu Dian-Na
BackgroundHerpes simplex virus type 1 (HSV‐1)‐mediated oncolytic therapy is a promising cancer treatment modality. However, viral tropism is considered to be one of the major stumbling blocks to the development of HSV‐1 as an anticancer agent.MethodsThe surface of oncolytic HSV‐1 G207 was covalently modified with folate‐poly (ethylene glycol) conjugate (FA‐PEG). The specificities and tumor targeting efficiencies of modified or unmodified G207 particles were analyzed by a real‐time polymerase chain reaction at the level of cell attachment and entry. Immune responses were assessed by an interleukin‐6 release assay from RAW264.7 macrophages. Biodistribution andin vivoantitumoral activity after intravenous delivery was evaluated in BALB/c nude mice bearing subcutaneous KB xenograft tumors.ResultsFA‐PEG‐HSV exhibited enhanced targeting specificity for folate receptor over‐expressing tumor cells and had lower immunogenicity than the unmodified HSV.In vivo, the FA‐PEG‐HSV group revealed an increased anti‐tumor efficiency and tumor targeting specificity compared to the naked HSV.ConclusionsThese results indicate that folate‐conjugated HSV G207 presents a folate receptor‐targeted oncolytic virus with a potential therapeutic value via retargeting to tumor cells.
